EICHORCondition: Lung Cancer, Non-Small Cell · Sponsor: GlaxoSmithKline
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Ocala, Florida, United States | — |
| GSK Investigational Site | Honolulu, Hawaii, United States | — |
| GSK Investigational Site | Lexington, Kentucky, United States | — |
| GSK Investigational Site | Lexington, Kentucky, United States | — |
| GSK Investigational Site | Omaha, Nebraska, United States | — |
| GSK Investigational Site | Nashville, Tennessee, United States | — |
| GSK Investigational Site | Fort Worth, Texas, United States | — |
| GSK Investigational Site | Olympia, Washington, United States | — |
| GSK Investigational Site | Buenos Aires, Argentina | — |
| GSK Investigational Site | Cipoletti Rio Negro, Argentina | — |
| GSK Investigational Site | Ciudad Autonoma de Buenos Aire, Argentina | — |
| GSK Investigational Site | Ciudad Autonoma de Bueno, Argentina | — |
+ 96 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06472076